ACUTE INTERVENTION MANAGEMENT STRATEGIES (AIMS)

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。目前治疗呼吸系统疾病期间急性喘息发作的方法包括支气管扩张剂。如果症状持续或恶化，应添加口服类固醇。临床经验表明，胸部症状可能在疾病晚期出现，即使在喘息发作时（感冒症状发作后2-3天）口服类固醇，效果也往往很差。这些因素导致急诊就诊和住院率高。根据该方案，我们建议在呼吸道疾病发病时开始吸入布地奈德或口服孟鲁司特治疗，以减少疾病期间的喘息次数，增加无症状天数，并延长口服类固醇的起始时间。本研究邀请不同种族的健康男女（12-59个月）参加。受试者必须相对健康，除非患有与呼吸系统疾病相关的中重度间断性喘息。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Current treatment for acute wheezing episodes during a respiratory illness includes bronchodilators. If symptoms continue or worsen, oral steroids are added. Clinical experience has shown that chest symptoms may develop late in the illness and often respond poorly even when oral steroids are added at the onset of wheezing (2-3 days after onset of cold symptoms). These factors contribute to a high rate of ER visits and hospitalizations. With this protocol, we propose to start treatment of inhaled budesonide or oral montelukast at the onset of a respiratory tract illness to decrease the amount of wheezing during the illness, increase the number of symptom-free days, and prolong the time to initiation of oral steroids. Healthy males and females (12-59 months) of diverse ethnicities were invited to join this study. Subjects must be relatively healthy other than having moderate-severe intermittent wheezing related to respiratory illnesses.